All News

Among surprises from a new study on U.S. health spending is the realization: Whether insured or not, young adults spent about the same on out-of-pocket health expenditures throughout the year.

As provider reimbursement begins to move toward models that favor quality over quantity, CEO compensation may be following the same path-with CEO pay determined more by quality measures than strictly by financial gains.

Quality-of-care performance means more to CEO paychecks at some for-profit hospital companies than at others.

Older breast cancer patients who received radiation treatment after surgery were more likely to undergo a more expensive and somewhat controversial type of radiation called brachytherapy if they got their care at for-profit rather than nonprofit hospitals, a new study reports.

PD-L1 protein levels could be an important biomarker to predict response to immunotherapy in NSCLC patients.

The American Society for Radiation Oncology (ASTRO) has issued a new guideline, The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline, that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. The guideline's executive summary is published in the May-June 2014 issue of Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO. The full-length guideline is available as an open-access article online.

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

Providers and insurers alike know that focusing on quality and cost will be essential, especially as healthcare shifts toward accountable care models.

With the delay in ICD-10, many insurers now have to slow down a mammoth IT project and, potentially more disruptive, make adjustments to a whole slew of programs and contracts.

Medicaid-financed emergency room costs statewide grew nearly $10 million to $178.3 million in fiscal year 2013.

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer, according to researchers.

Randomized trial to evaluate immune activation following treatment with immunotherapy combination. The open label design will allow for ongoing evaluation of clinical results from study.

Despite enrollment deadline extensions and expansion of the federal poverty guidelines, many uninsured Americans are choosing not to obtain health plans on insurance exchanges.

The U.S. Food and Drug Administration today approved the first FDA-approved HPV DNA test for women 25 and older that can be used alone to help a health care professional assess the need for a woman to undergo additional diagnostic testing for cervical cancer. The test also can provide information about the patient's risk for developing cervical cancer in the future.

Look beyond the EHR incentive program. A national effort to turn CMS's recent release of Medicare physician payment data into useful, actionable data visualizations is the hottest HIT challenge right now.

The expenses associated with cancer care in the United States are staggering and only expected to climb.

- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today that the United States Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo, an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at this time.

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

AJMC Panel Reviews Treatment, Cost Impacts of Emerging Shift to All-Oral Regimens With High Cure Rates

A blood test performed before radical cystectomy in patients with urothelial cancer of the bladder could identify the presence of circulating tumor cells (CTCs), which are predictive of outcome, according to a new study.